Transcription activation of FLRG and follistatin by activin A, through smad proteins, participates in a negative feedback loop to modulate activin a function.
Abstract
Signaling of TGFbeta family members such as activin is tightly regulated by soluble binding proteins. Follistatin binds to activin A with high affinity, and prevents activin binding to its own receptors, thereby blocking its signaling. We previously identified FLRG gene from a B-cell leukemia carrying a t(11;19)(q13;p13) translocation. We and others have already shown that FLRG, which is highly homologous to follistatin, may be involved in the regulation of the activin function through its binding to activin. In this study, we found that, like follistatin, FLRG protein inhibited activin A signaling as demonstrated by the use of a transcriptional reporter assay, and blocked the activin A-induced growth inhibition of HepG2 cells. We have recently shown that the TGFbeta-induced expression of FLRG occurs at a transcriptional level through the action of Smad proteins. Here we show that activin A increases FLRG and follistatin at both the mRNA and protein levels. We found that Smad proteins are involved in the activin A-induced transcription activation of FLRG and follistatin. Finally we demonstrate that FLRG protein regulates its own activin-induced expression. In conclusion, activin A induces FLRG and follistatin expression. This observation, in conjunction with the antagonistic effect of FLRG and follistatin on activin signaling, indicates that these two proteins participate in a negative feedback loop which regulates the activin function.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
When ligand levels diminish, attenuators also diminish and receptors increase; signaling re-boot induces negative regulators, as observed for follistatin and follistatin-like, secondarily diminishing the intensity of age-elevated pathways.
“When the levels of ligand(s) diminish, attenuators also diminish, and receptor(s) increase [62, 63]; signaling re-boot induces negative regulators, as we observed for follistatin and follistatin-like, secondarily diminishing the intensity of age-elevated pathways [64–66].”
From Rejuvenation of three germ layers tissues by exchanging old blood plasma with saline-albumin (2020) · cites this paper as [64]
Cites
Regulation of the expression of follistatin in rat hepatocytes
Zhang, Y.-Q., Kanzaki, M., Shibata, H., & Kojima, I. (1997) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(97)00085-7 · Cited by 36 · see citing works
Flagged first, then by citations
Research works printed but not linked: 42
- Bartholin L, Maguer-Satta V, Hayette S, Martel S, Gadoux M, Bertrand S, Corbo L, Lamadon C, Morera A, Magaud J, Rimokh R . 2001 Oncogene 20: 5409–5419 · DOI
- Bitzer M, von Gersdorff G, Liang D, Dominguez-Rosales A, Beg AA, Rojkind M, Bottinger EP . 2000 Genes Dev. 14: 187–197 · DOI
- Brodin G, Ahgren A, ten Dijke P, Heldin CH, Heuchel R . 2000 J. Biol. Chem. 275: 29023–29030 · DOI
- de Winter JP, ten Dijke P, de Vries CJ, van Achterberg TA, Sugino H, de Waele P, Huylebroeck D, Verschueren K, van den Eijnden-van Raaij AJ . 1996 Mol. Cell. Endocrinol. 116: 105–114 · DOI
- Denissova NG, Pouponnot C, Long J, He D, Liu F . 2000 Proc. Natl. Acad. Sci. USA 97: 6397–6402 · DOI
- Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM . 1998 EMBO J. 17: 3091–3100 · DOI
- DePaolo LV . 1997 Proc. Soc. Exp. Biol. Med. 214: 328–339 · DOI
- Derynck R, Zhang Y, Feng XH . 1998 Cell 95: 737–740 · DOI
- Fainsod A, Deissler K, Yelin R, Marom K, Epstein M, Pillemer G, Steinbeisser H, Blum M . 1997 Mech. Dev. 63: 39–50 · DOI
- Gamer LW, Wolfman NM, Celeste AJ, Hattersley G, Hewick R, Rosen V . 1999 Dev. Biol. 208: 222–232 · DOI
- Gazzerro E, Gangji V, Canalis E . 1998 J. Clin. Invest. 102: 2106–2114 · DOI
- Hayashi H, Abdollah S, Qiu Y, Cai J, Xu YY, Grinnell BW, Richardson MA, Topper JN, Gimbrone Jr MA, Wrana JL, Falb D . 1997 Cell 89: 1165–1173 · DOI
- Hayette S, Gadoux M, Martel S, Bertrand S, Tigaud I, Magaud JP, Rimokh R . 1998 Oncogene 16: 2949–2954 · DOI
- Iemura S, Yamamoto TS, Takagi C, Uchiyama H, Natsume T, Shimasaki S, Sugino H, Ueno N . 1998 Proc. Natl. Acad. Sci. USA 95: 9337–9342 · DOI
- Imamura T, Takase M, Nishihara A, Oeda E, Hanai J, Kawabata M, Miyazono K . 1997 Nature 389: 622–626 · DOI
- Lagna G, Hata A, Hemmati-Brivanlou A, Massague J . 1996 Nature 383: 832–836 · DOI
- Lebrun JJ, Takabe K, Chen Y, Vale W . 1999 Mol. Endocrinol. 13: 15–23 · DOI
- Maguer-Satta V, Bartholin L, Jeanpierre S, Gadoux M, Bertrand S, Martel S, Magaud JP, Rimokh R . 2001 Exp. Hematol. 29: 301–308 · DOI
- Massague J, Wotton D . 2000 EMBO J. 19: 1745–1754 · DOI
- Moustakas A, Kardassis D . 1998 Proc. Natl. Acad. Sci. USA 95: 6733–6738 · DOI
- Nagarajan RP, Zhang J, Li W, Chen Y . 1999 J. Biol. Chem. 274: 33412–33418 · DOI
- Nakamura T, Takio K, Eto Y, Shibai H, Titani K, Sugino H . 1990 Science 247: 836–838 · DOI
- Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R, Itoh S, Kawabata M, Heldin NE, Heldin CH, ten Dijke P . 1997 Nature 389: 631–635 · DOI
- Pereira RC, Economides AN, Canalis E . 2000 Endocrinology 141: 4558–4563 · DOI
- Phillips DJ . 2000 Bioessays 22: 689–696 · DOI
- Phillips DJ, de Kretser DM . 1998 Front. Neuroendocrinol. 19: 287–322 · DOI
- Piek E, Heldin CH, Ten Dijke P . 1999 Faseb J. 13: 2105–2124 · DOI
- Reddi AH . 2001 Arthritis Res. 3: 1–5 · DOI
- Russell CE, Hedger MP, Brauman JN, de Kretser DM, Phillips DJ . 1999 Mol. Cell. Endocrinol. 148: 129–136 · DOI
- Schwall RH, Robbins K, Jardieu P, Chang L, Lai C, Terrell TG . 1993 Hepatology 18: 347–356 · DOI
- Shimasaki S, Koga M, Esch F, Cooksey K, Mercado M, Koba A, Ueno N, Ying SY, Ling N, Guillemin R . 1988 Proc. Natl. Acad. Sci. USA 85: 4218–4222 · DOI · Paper page
- Smith WC . 1999 Trends Genet. 15: 3–5 · DOI
- Takase M, Imamura T, Sampath TK, Takeda K, Ichijo H, Miyazono K, Kawabata M . 1998 Biochem. Biophys. Res. Commun. 244: 26–29 · DOI
- ten Dijke P, Miyazono K, Heldin CH . 2000 Trends Biochem. Sci. 25: 64–70 · DOI
- Tsuchida K, Arai KY, Kuramoto Y, Yamakawa N, Hasegawa Y, Sugino H . 2000 J. Biol. Chem. 275: 40788–40796 · DOI
- Ulloa L, Doody J, Massague J . 1999 Nature 397: 710–713 · DOI
- Vindevoghel L, Lechleider RJ, Kon A, de Caestecker MP, Uitto J, Roberts AB, Mauviel A . 1998 Proc. Natl. Acad. Sci. USA 95: 14769–14774 · DOI
- Wrana JL . 2000 Cell 100: 189–192 · DOI
- Yamashita T, Takahashi S, Ogata E . 1992 Blood 79: 304–307 · DOI
- Yasuda H, Mine T, Shibata H, Eto Y, Hasegawa Y, Takeuchi T, Asano S, Kojima I . 1993 J. Clin. Invest. 92: 1491–1496 · DOI
- Ying SY, Zhang Z, Furst B, Batres Y, Huang G, Li G . 1997 Proc. Soc. Exp. Biol. Med. 214: 114–122 · DOI
- Zhang Y, Feng X, We R, Derynck R . 1996 Nature 383: 168–172 · DOI
Cited by
Sorted by citations
Bone Morphogenetic Protein-2 in Development and Bone Homeostasis
Halloran, D., Durbano, H. W., & Nohe, A. (2020) · Journal of Developmental Biology · doi:10.3390/jdb8030019 · Cited by 348 · see citing works
Rejuvenation of three germ layers tissues by exchanging old blood plasma with saline-albumin
Mehdipour, M., Skinner, C., Wong, N., Lieb, M., Liu, C., Etienne, J., Kato, C., Kiprov, D., Conboy, M. J., & Conboy, I. M. (2020) · Aging · doi:10.18632/aging.103418 · Cited by 115 · see citing works
Clinical and therapeutic implications of follistatin in solid tumours
SHI, L., RESAUL, J., OWEN, S., YE, L., & JIANG, W. G. (2016) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20005 · Cited by 47 · see citing works
- Authors
- Bartholin, L., Maguer-Satta, V., Hayette, S., Martel, S., Gadoux, M., Corbo, L., Magaud, J.-P., & Rimokh, R.
- Venue
- Oncogene
- Published
- 2002-03-28
- Volume
- 21
- Issue
- 14
- Pages
- 2227-2235
- ISSN
- 0950-9232
- 1476-5594
- Cited by
- 82
- References
- 1
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review